DK2484669T3 - Fenolderivat - Google Patents

Fenolderivat Download PDF

Info

Publication number
DK2484669T3
DK2484669T3 DK10820564.2T DK10820564T DK2484669T3 DK 2484669 T3 DK2484669 T3 DK 2484669T3 DK 10820564 T DK10820564 T DK 10820564T DK 2484669 T3 DK2484669 T3 DK 2484669T3
Authority
DK
Denmark
Prior art keywords
added
mixture
dihydro
distilled
solvent
Prior art date
Application number
DK10820564.2T
Other languages
Danish (da)
English (en)
Inventor
Seiichi Kobashi
Junichiro Uda
Sachiho Miyata
Tsutomu Inoue
Naoki Ashizawa
Koji Matsumoto
Tetsuya Taniguchi
Takashi Iwanaga
Osamu Nagata
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2484669(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Application granted granted Critical
Publication of DK2484669T3 publication Critical patent/DK2484669T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK10820564.2T 2009-09-30 2010-09-29 Fenolderivat DK2484669T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体
PCT/JP2010/066925 WO2011040449A1 (ja) 2009-09-30 2010-09-29 新規フェノール誘導体

Publications (1)

Publication Number Publication Date
DK2484669T3 true DK2484669T3 (en) 2015-09-21

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10820564.2T DK2484669T3 (en) 2009-09-30 2010-09-29 Fenolderivat

Country Status (23)

Country Link
US (1) US8367843B2 (OSRAM)
EP (1) EP2484669B1 (OSRAM)
JP (1) JP5325065B2 (OSRAM)
KR (1) KR101647174B1 (OSRAM)
CN (1) CN102639518B (OSRAM)
AU (1) AU2010301675B2 (OSRAM)
BR (1) BR112012007069B1 (OSRAM)
CA (1) CA2775309C (OSRAM)
DK (1) DK2484669T3 (OSRAM)
ES (1) ES2549603T3 (OSRAM)
HU (1) HUE026007T2 (OSRAM)
IL (1) IL218519A (OSRAM)
IN (1) IN2012DN02551A (OSRAM)
MX (1) MX2012003392A (OSRAM)
MY (1) MY160394A (OSRAM)
NZ (1) NZ598582A (OSRAM)
PH (1) PH12012500643A1 (OSRAM)
PL (1) PL2484669T3 (OSRAM)
PT (1) PT2484669E (OSRAM)
RU (1) RU2536689C2 (OSRAM)
TW (1) TWI461195B (OSRAM)
WO (1) WO2011040449A1 (OSRAM)
ZA (1) ZA201201895B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
WO2017038799A1 (ja) * 2015-09-04 2017-03-09 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
HUE051448T2 (hu) * 2015-09-10 2021-03-01 Jiangsu Atom Bioscience Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
EP3957629B1 (en) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Process for making deuterated hydroxy-benzbromarone and intermediates thereof
BR112019018840B1 (pt) 2017-04-28 2023-12-19 Fuji Yakuhin Co., Ltd Forma cristalina de 3-(3,5-dicloro-4-hidroxibenzoil)-1,1-dioxo-2,3-dihidro 1,3 -benzotiazol
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
EP4074313A4 (en) * 2019-12-09 2024-01-03 Fuji Yakuhin Co., Ltd. SOLID PHARMACEUTICAL PREPARATION
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
US7521570B2 (en) 2004-06-10 2009-04-21 Torli Pharmaceutical Co., Ltd. Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
EP1985297A1 (en) * 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Also Published As

Publication number Publication date
NZ598582A (en) 2013-04-26
IL218519A (en) 2016-03-31
TW201121544A (en) 2011-07-01
ES2549603T3 (es) 2015-10-29
AU2010301675A1 (en) 2012-04-05
JP2011074017A (ja) 2011-04-14
CN102639518A (zh) 2012-08-15
EP2484669B1 (en) 2015-07-29
CA2775309A1 (en) 2011-04-07
US8367843B2 (en) 2013-02-05
HUE026007T2 (en) 2016-05-30
AU2010301675B2 (en) 2013-08-22
KR20120080183A (ko) 2012-07-16
RU2536689C2 (ru) 2014-12-27
MX2012003392A (es) 2012-04-10
TWI461195B (zh) 2014-11-21
KR101647174B1 (ko) 2016-08-09
MY160394A (en) 2017-03-15
HK1169650A1 (en) 2013-02-01
US20120184587A1 (en) 2012-07-19
CN102639518B (zh) 2015-03-25
ZA201201895B (en) 2013-09-25
IN2012DN02551A (OSRAM) 2015-08-28
PT2484669E (pt) 2015-10-30
EP2484669A4 (en) 2013-02-27
IL218519A0 (en) 2012-07-31
JP5325065B2 (ja) 2013-10-23
PH12012500643A1 (en) 2012-11-12
BR112012007069A2 (pt) 2016-04-19
CA2775309C (en) 2017-12-12
EP2484669A1 (en) 2012-08-08
BR112012007069B1 (pt) 2020-03-03
WO2011040449A1 (ja) 2011-04-07
PL2484669T3 (pl) 2015-12-31
RU2012117786A (ru) 2013-11-10

Similar Documents

Publication Publication Date Title
DK2484669T3 (en) Fenolderivat
JP6569792B2 (ja) ハロゲン置換へテロ環化合物
US20040248950A1 (en) Apo ai expression accelerating agent
TW201117809A (en) Substituted amide compounds
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
TW200400027A (en) Compounds that modulate PPAR activity
WO2007043457A1 (ja) トリアリールカルボン酸誘導体
WO2007097403A1 (ja) 消化管潰瘍治療又は予防薬
CN106008340A (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
WO2007102515A1 (ja) フェニルチアゾール誘導体
CN102627638A (zh) 噻二唑取代的香豆素衍生物及其作为白三烯生物合成抑制剂的用途
WO2006022375A1 (ja) 2-フェニルチオフェン誘導体
WO1990005132A1 (fr) Derives d'allylamine substitues, procede de preparation et utilisation
US20220289698A1 (en) Inhibitors of human atgl
HK1169650B (en) Novel phenol derivative
EP3924329A2 (en) Substituted amide compounds useful as farnesoid x receptor modulators
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用
WO2000044756A1 (en) Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof